AET Laboratories Private Ltd. is a private pharmaceutical company founded in 2003 and headquartered in Sangareddy, Telangana, India. It is a subsidiary of the Germany-based, family-owned Tiefenbacher Group. As of late 2024, the company had approximately 331 employees. For the fiscal year ending March 2022, its operating revenue was in the range of ₹100 crore to ₹500 crore (INR).
The company operates as a manufacturer of generic medications, focusing on research, development, and production of finished dosage forms (FDFs). Its product portfolio includes solid oral medications like tablets and capsules. The company's manufacturing activities cover several therapeutic areas, including anthelmintics (anti-parasitic drugs), antimalarials, and respiratory medicines. AET Laboratories serves both domestic and international markets, and its facilities have been approved by international regulatory bodies, including the US FDA.
AET Laboratories' patent litigation profile is that of an operating company defending its products. Based on the provided data, the company has been a defendant in one tracked US patent case and has not been a plaintiff. This posture is typical for a generic pharmaceutical manufacturer facing infringement suits from brand-name drug companies upon seeking to market a generic version of a patented drug.
The company's single tracked case is Harmony Biosciences Management Inc et al. v. AET Pharma US Inc et al., filed in the Delaware District Court in April 2026. In this suit, AET Laboratories Private Ltd. is a co-defendant alongside its US affiliate, AET Pharma US Inc., its parent company Alfred E. Tiefenbacher, and Sandoz entities. This litigation aligns with its business of manufacturing generic pharmaceuticals.